Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma). Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers. Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure. We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.

Eligibility Criteria

Inclusion Criteria:

prior asbestos exposure at least 20 years ago and/or documented pleural plaques (chest x-ray evidence)

Resident of Ontario, Canada

Exclusion Criteria:

prior cancer (except non-melanotic skin cancer)

Trial Contact Information

Trial Lead Organizations/Sponsors

Toronto Western Hospital

Demetris Patsios, MD

Principal Investigator

Marc de Perrot, MD

Principal Investigator

Demetris Patsios, MD		Ph: Tel: (416) 603-5800 Ext.2583
		Email: demetris.patsios@uhn.on.ca

Canada
Ontario
	Toronto
		Brenda O'Sullivan, MD	Ph: 416-340-4800 Ext.5686
			Email: brenda.o'sullivan@uhn.on.ca
	Princess Margaret Hospital
		Demetris Patsios, MD	Ph: Tel: (416) 603-5800 Ext.2583
			Email: demetris.patsios@uhn.on.ca

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00188890
Information obtained from ClinicalTrials.gov on November 20, 2012

Back to Top